European patent granted for XL-protein’s PASylation® technology

FREISING, GERMANY, MARCH 17th, 2011 – XL-protein GmbH, a German biotech company that specialises in the development of biopharmaceuticals with extended plasma half-life, today announced that the European Patent Office granted a core patent (EP2173890) for XL-protein’s PASylation® technology. Beside the granted PASylation® EP patent, several other corresponding national patent applications are currently processed worldwide. […]

Phylogica collaborates with XL-protein on inflammation Program

XL-protein Collaborates with Phylogica on Inflammation Program PERTH, AUSTRALIA, January 13, 2011 – Phylogica Ltd (ASX: PYC), a leading Australian-based drug discovery company, announced today an alliance with XL-protein GmbH, a German-based biotech company that specialises in extending the circulation half-life of biopharmaceuticals. Through this alliance, Phylogica gains access to a unique modification technology that […]

The Bavarian Patent Alliance GmbH and the biotech company XL-protein GmbH have signed an exclusive licensing agreement on a promising invention of the Technical University of Munich

München, Germany, September 17, 2009 The Bavarian Patent Alliance GmbH and the biotech company XL-protein GmbH have signed an exclusive licensing agreement on a promising invention of the Technical University of Munich. With the so-called “PASylation technology” the plasma half-life of biological agents is extended manifold. Therapeutic proteins are directly fused on the genetic level […]